8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
BIOGEN INC. (BIIB)

Biogen ($BIIB) filed a Form 8‑K on Feb 6, 2026 furnishing a press release dated Feb 6, 2026 (Exhibit 99.1)…

Filed with the SEC on · Summarized by InvestorsBot

Biogen ($BIIB) filed a Form 8‑K on Feb 6, 2026 furnishing a press release dated Feb 6, 2026 (Exhibit 99.1) and the Cover Page Inline XBRL file (Exhibit 104). Report signed by Wendell Taylor, Secretary. 📄 #8K #SECfiling #Biotech

8‑K contains exhibits only — investors should read Biogen’s Feb 6, 2026 press release (Exhibit 99.1) for the substantive news and potential market impact. $BIIB 🔍 #Investing #Biotech

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from BIOGEN INC.

Biogen ($BIIB) announced Chief Legal Officer Susan H.

8-K · March 11, 2026

Biogen ($BIIB) Board elected Dr.

8-K · February 11, 2026

Feb 11, 2026 — Biogen Board Chair Caroline Dorsa announced she will not stand for re‑election at the 2026…

8-K · February 11, 2026

Biogen ($BIIB) on Feb 6, 2026 issued a press release announcing results of operations & financial…

8-K · February 6, 2026

Biogen expects a ~$222M pre-tax acquired IPR&D/upfront & milestone charge in Q4 2025, cutting GAAP and…

8-K · January 14, 2026